Last reviewed · How we verify
NCT06897098
Regeneration of Knee and Ankle Cartilage From Autologous Cartilage Mini-grafts (From the Patient's Own Cells)
Phase 1 trial testing Implantation of autologous cartilage mini-grafts (Cartibeads) in Cartilage Repair in 11 participants. Participants enrolled and being followed up; not accepting new ones.
2 April 2025
Quick facts
| Lead sponsor | Vanarix SA |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 10 June 2022 |
| Primary completion | 2 April 2025 |
| Estimated completion | 2 April 2025 |
| Sites | 3 locations across Switzerland |
Drugs / interventions tested
- Implantation of autologous cartilage mini-grafts (Cartibeads) — full drug profile →
Conditions studied
- Cartilage Repair — all drugs for Cartilage Repair →
Sponsor
Vanarix SA — full company profile →
Who can join
18 and older, any sex, with Cartilage Repair. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the safety and feasibility of implanting autologous cartilage mini-grafts (or Cartibeads) into cartilage defects in the knee and ankle. Cartibeads are engineered from autologous articular chondrocytes (from the patient's own cartilage cells). A small cartilage biopsy (\~50 to 150 mg according to lesion size to be treated) is collected from a minimal weight bearing zone of the patient's articulation. Chondrocytes are extracted from the biopsy and expanded in culture. Our patented, standardized methodology then allows expanded cells to recover their capacity of producing hyaline matrix and to form cartilage mini-grafts (Cartibeads). These grafts are beads of 1 to 2 mm in diameter and have similar characteristics to native hyaline cartilage. Autologous Cartibeads are implanted into the patient's cartilage defect. Patients are then followed for 12 months for assessment of study endpoints, with safety being the primary outcome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Biocompatible Stimuli-Sensitive Natural Hydrogels: Recent Advances in Biomedical Applications.
Calderon Moreno JM, Chelu M, Popa M. · · 2025 · PMID 41441149 · DOI 10.3390/gels11120993
Verify or expand the search:
- PubMed search for NCT06897098
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cartilage Repair
Currently open trials in the same condition.
- NCT06897111 — Implantation of Cartilage Mini-grafts Made From Donor Cells to Treat Chondral Lesions of the Knee · Phase 1, PHASE2 · active not recruiting
Other Vanarix SA trials
Trials by the same sponsor.
- NCT06897111 — Implantation of Cartilage Mini-grafts Made From Donor Cells to Treat Chondral Lesions of the Knee · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06897098 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vanarix SA
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06897098.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing